Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 2545 - 2552 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC7103 | SNC 162 |
|
Potent and selective non-peptide <span class='symbol'>δ</span>-opioid receptor agonist (K<sub>i</sub> = 0.63 nM). Displays > 8000-fold selectivity over <span class='symbol'>μ</span>-opioid receptors and is centrally active following systemic administration <em>in vivo</em>.
|
|
| BCC7104 | A 68930 hydrochloride |
|
Potent and selective D1-like dopamine receptor agonist (EC50 values are 2.1 and 3910 nM for D1-like and D2-like receptors respectively). Centrally active following systemic administration in vivo.
|
|
| BCC7105 | DCPIB |
|
Potent, selective blocker of the volume-sensitive anion channel (VSAC) in rat pancreatic <span class='symbol'>β</span>-cells (IC<sub>50</sub> ~ 2 <span class='symbol'>μ</span>M) and I<sub>Cl,swell</sub> in various cardiovascular tissues (IC<sub>50</sub> = 4.1 <span class='symbol'>μ</span>M in CPAE cells); blockade is voltage-independent. Displays minimal inhibition of other Cl<sup>-</sup> and K<sup>+</sup> currents (< 10% inhibition at 10 <span class='symbol'>μ</span>M). Inhibits glucose-stimulated insulin secretion in intact <span class='symbol'>β</span>-cells via VSAC inhibition and indirect K<sub>ATP</sub> channel activation. Reverses cell swelling-induced action potential duration shortening in atrial myocytes and inhibits astroglial swelling <em>in vitro</em>.
|
|
| BCC7106 | (S)-CPW 399 |
|
Novel subtype-selective and weakly desensitizing AMPA receptor partial agonist (K<sub>i</sub> values are 44, 109, 223, 1890 and 2090 nM at GluR5, GluR1, GluR2, GluR3 and GluR4 receptors respectively). Exhibits potent agonist activity at GluR1 and GluR2 subunit-containing AMPA receptors (EC<sub>50</sub> values are 24.9 and 13.9 <span class='symbol'>μ</span>M respectively) and is excitotoxic <em>in vitro</em>.
|
|
| BCC7107 | (R)-(+)-Bay K 8644 |
|
L-type Ca<sup>2+</sup>-channel blocker with negative inotropic and vasodilatatory effects <em>in vivo</em>. Enantiomer showing opposite effects to the racemate (±)-Bay K 8644 and (S)-(-)- enantiomer.
|
|
| BCC7108 | (S)-(-)-Bay K 8644 |
|
L-type Ca<sup>2+</sup>-channel activator with positive inotropic, vasoconstrictive and behavioral effects <em>in vivo</em>. Enantiomer of (±)-Bay K 8644.
|
|
| BCC7109 | NSC 95397 |
|
Potent and selective irreversible inhibitor of Cdc25 dual specificity phosphatases (Ki values are 32, 96 and 40 nM for inhibition of Cdc25A, -B and -C respectively). Displays 125 - 180-fold selectivity over VH1-related dual-specificity phosphatase and protein tyrosine phosphatase 1b. Inhibits carcinoma cell growth and blocks G2/M phase transition in vitro.
|
|
| BCC7110 | CD 437 |
|
Synthetic retinoid that is an RAR<span class='symbol'>γ</span>-selective agonist. Displays RAR<span class='symbol'>γ</span>-dependent and -independent effects on differentiation and apoptosis.
|
|